Patients exploring ketamine therapy in New York will generally encounter two primary approaches: FDA-approved Spravato (esketamine) and off-label ketamine formulations. Spravato is an FDA-approved nasal spray indicated for adults with treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. Because of its FDA status, Spravato is often eligible for health insurance coverage, though patients usually face a rigorous prior authorization process to verify eligibility.
In contrast, treatments such as IV infusions, intramuscular injections, and sublingual ketamine are prescribed off-label for psychiatric conditions. Insurance rarely covers these compounded treatments, requiring most patients to pay out-of-pocket. The FDA has warned about risks associated with these unregulated medications; further information is available here: FDA warns patients and health care providers about potential risks associated with compounded ketamine products.
Financial Planning for Long Island Patients
Beyond the clinical fees for administration and observation, patients must account for the indirect costs of treatment. Traveling from Freeport to clinics in Melville or Manhattan incurs expenses related to gas, tolls, transit fares, and potential parking fees. Clinics will supply a written estimate of treatment costs upon request, helping patients budget for the full sequence of repeated visits.